Clinical peptide vaccination trials for leukemia patients

Expert Review of Vaccines

Volumn 10, Issue 6, 2011, Pages 785-799

  Casalegno Garduno R ^a   Schmitt, A ^a   Schmitt, M ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

bcr abl; clinical trials; leukemia; peptide vaccine; PR 3; RHAMM; WT1

Indexed keywords

ARGINYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLTYROSYLLEUCINE; ARGINYLSERYLASPARTYLGLUTAMYLLEUCYLVALYLARGINYLHISTIDYLHISTIDYLASPARAGINYLMETHIONYLHISTIDYLGLUTAMINYLARGINYLASPARAGINYLMETHIONYLTHREONYLLYSYLLEUCINE; BCR ABL PROTEIN; CYSTEINYLMETHIONYLTHREONYLTRYPTOPHANYLASPARAGINYLGLUTAMINYLMETHIONYLASPARAGINYLLEUCINE; CYSTEINYLTYROSYLTHREONYLTRYPTOPHANYLASPARAGINYLGLUTAMINYLMETHIONYLASPARAGINYLLEUCINE; HYALURONIC ACID BINDING PROTEIN; ISOLEUCYLLEUCYLSERYLLEUCYLGLUTAMYLLEUCYLMETHIONYLLYSYLLEUCINE; LEUKEMIA ANTIGEN; MYELOBLASTIN; PEPTIDE VACCINE; PROLYLGLYCYLCYSTEINYLASPARAGINYLLYSYLARGINYLTYROSYLPHENYLALANYLLYSYLLEUCYLSERYLHISTIDYLLEUCYLGLUTAMINYLMETHIONYLHISTIDYLSERYLARGINYLLYSYLHISTIDYLTHREONYLGLYCINE; SERYLGLYCYLGLUTAMINYLTYROSYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLLEUCYLPROLYLSERYLCYSTEINYLLEUCYLGLUTAMYLSERINE; TUMOR SUPPRESSOR PROTEIN; TYROSYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLTYROSYLLEUCINE; UNCLASSIFIED DRUG; WILMS TUMOR 1;

ACUTE GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; HLA SYSTEM; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LEUKEMIA; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 79959562512     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.56     Document Type: Review

References (83)

1. Greiner J, Ringhoffer M, Taniguchi M et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic tumor-associated antigen overexpressed in acute and chronic myeloid leukemia. Exp. Hematol. 30, 1029-1025 (2002
2. Greiner J, Ringhoffer M, Taniguchi M et al. Characterization of several leukemia associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CMLInt. J. Cancer 106, 224-231 (2003 (Pubitemid 36835175)
3. Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia (AML) - definition of targets and current clinical protocols (reviewHaematologica 91, 1653-1661 (2006 (Pubitemid 46039635)
4. Greiner J, Guinn B, Döhner H et al. Leukemia-associated antigens (LAAs) are critical for the proliferation of acute myeloid leukemia cells. Clin. Cancer Res. 14, 1-6 (2008
5. Ochi T, Fujiwara H, Suemori K et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 113, 66-74 (2009
6. Sokal JE, Aungst CW, Snyderman M, Gomez G. Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules. Ann. NY Acad. Sci. 277, 367-383 (1976
7. Alsabti EA, Taleb AM, Raji HM et al. Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia. Jpn J. Exp. Med. 49, 157-168 (1979 (Pubitemid 9257489)
8. Alexander P, Powles R. Immunotherapy of human acute leukaemia. Clin. Haematol. 2, 275-294 (1978).
9. Cignetti A, Vallario A, Roato I et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J. Immunol. 173, 2855-2865 (2004 (Pubitemid 39063148)
10. Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother. 54, 685-693 (2005 (Pubitemid 40884165)
11. Schmitt M, Schmitt A, Rojewski M et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. Blood 111, 1357-1365 (2008 (Pubitemid 351213422)
12. Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909. Cancer Immunol. Immunother. 60, 161-171 (2011
13. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746 (2005 (Pubitemid 40322250)
14. Adams S, O'Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181, 776-784 (2008
15. Greiner J, Schmitt A, Giannopoulos K et al. High-dose RHAMM-R3 peptide peptide vaccination for patients with vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95, 1191-1197 (2010
16. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT-1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT-1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101, 13885-13890 (2004 (Pubitemid 39298502)
17. Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 116, 171-179 (2010
18. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365, 657-662 (2005 (Pubitemid 40260886)
19. Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT-1) peptide vaccination in patients with AML and MDS. Blood 113, 6541-6548 (2009
20. Barrett J, Rezvani K. Immunotherapy: can we include vaccines with stem-cell transplantation? Nat. Rev. Clin. Oncol. 6, 503-505 (2009
21. Greiner J, Li L, Ringhoffer M et al. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. Blood 106, 938-945 (2005 (Pubitemid 41076438)
22. Turley EA. Purification of a hyaluronate-binding protein fraction that modifies cell social behavior. Biochem. Biophys. Res. Commun. 108, 1016-1024 (1982 (Pubitemid 13072654)
23. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J. Biol. Chem. 277, 4589-4592 (2002 (Pubitemid 34968484)
24. Hall CL, Yang B, Yang X et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 82, 19-26 (1995
25. Hall CL, Lange LA, Prober DA et al. pp60 (c-src) is required for cell locomotion regulated by the hyaluronan receptor RHAMM. Oncogene 13, 2213-2224 (1996 (Pubitemid 26411572)
26. Buganim Y, Rotter V. RHAMM in the complex p53 cell cycle network. Cell Cycle 7, 3287-3291 (2008
27. Slevin M, Krupinski J, Gaffney J et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 26, 58-68 (2007 (Pubitemid 46091650)
28. Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle 7, 3448-3460 (2008
29. Evanko SP, Tammi MI, Tammi RH, Wight TN. Hyaluronan dependent pericellular matrix. Adv. Drug Deliv. Rev. 59, 1351-1365 (2007
30. Samuel SK, Hurta RA, Spearman MA et al. TGF-b 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J. Cell Biol. 123, 749-758 (1993
31. Assmann V, Marshall JF, Fieber C et al. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J. Cell Sci. 111, 1685-1694 (1998 (Pubitemid 28330555)
32. Abetamann V, Kern HF, Elsässer HP. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin. Cancer Res. 2, 1607-1618 (1996 (Pubitemid 126447457)
33. Li H, Guo L, Li JW et al. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumour progression. Int. J. Oncol. 17, 927-932 (2000
34. Rein DT, Roehrig K, Schöndorf T et al. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis. J. Cancer Res. Clin. Oncol. 129, 161-164 (2003 (Pubitemid 36583696)
35. Teder P, Bergh J, Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res. 55, 3908-3914 (1995
36. Ahrens T, Assmann V, Fieber C et al. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Invest. Dermatol. 11, 93-101 (2000
37. Crainie M, Belch AR, Mant MJ. et al. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 93, 1684-1696 (1999 (Pubitemid 29102497)
38. + T cell-responses in patients with chronic lymphocytic leukemia. Leukemia 24, 798-805 (2010
39. Haber DA, Buckler AJ, Glaser T et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61, 1257-1269 (1990
40. Schmid D, Heinze G, Linnerth B et al. Prognostic significance of WT-1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 11, 639-643 (1997). (Pubitemid 27241240)
41. Cilloni D, Messa F, Arruga F et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT-1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 93, 921-924 (2008 (Pubitemid 351821731)
42. Greiner J, Ringhoffer M, Taniguchi M et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int. J. Cancer 108, 704-711 (2004 (Pubitemid 38076402)
43. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol. 112, 79-84 (2004 (Pubitemid 38716252)
44. Burwell EA, McCarty GP, Simpson LA et al. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Effects of WT1 isoforms on breast epithelial cells. Oncogene 26, 3423-3430 (2007 (Pubitemid 46788886)
45. Inoue K, Tamaki H, Ogawa H et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91, 2969-2976 (1998 (Pubitemid 28227548)
46. Algar EM, Khromykh T, Smith SI et al. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 12, 1005-1014 (1996 (Pubitemid 26104442)
47. Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164, 1873-1880 (2000 (Pubitemid 30108741)
48. Xue SA, Gao L, Thomas S et al. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 95, 126-134 (2010
49. + cytotoxic T-lymphocyte clone specific for WT-1 peptide. Blood 95, 286-293 (2000 (Pubitemid 30017254)
50. Bellantuono I, Gao L, Parry S et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100, 3835-3837 (2002 (Pubitemid 35303962)
51. Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT-1 product in patients with hematopoietic malignancies. Blood 99, 3272-3279 (2002 (Pubitemid 34525307)
52. Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 51, 99-107 (2000 (Pubitemid 30150969)
53. Weber G, Karbach J, Kuçi S et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 23, 1634-1642 (2009
54. Mailänder V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT-1 peptide in the absence of hematological or renal toxicity. Leukemia 18, 165-166 (2004 (Pubitemid 38159453)
55. + T cells in myeloid malignancies. Haematologica 96, 432-440 (2011
56. Narita M, Masuko M, Kurasaki T et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int. J. Med. Sci. 7, 72-81 (2010
57. Oji Y, Oka Y, Nishida S et al. WT1 peptide vaccine induces reduction in minimal residual disease in an imatinib-treated CML patient. Eur. J. Haematol. 85, 358-360 (2010
58. Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78, 56-61 (2003 (Pubitemid 36899903)
59. Dengler R, Munstermann U, Al-Batran S et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol. 89, 250-257 (1995
60. + T cells specific for human neutrophil elastase. Blood 103, 3076-3083 (2004 (Pubitemid 38451684)
61. Bories D, Raynal MC, Solomon DH et al. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59, 959-968 (1989 (Pubitemid 20024607)
62. + cells in CML patients identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival. Blood 107, 205-212 (2006 (Pubitemid 43053545)
63. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450-2457 (1996 (Pubitemid 26327493)
64. Molldrem JJ, Lee PP, Wang C et al. A PR-1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59, 2675-2681 (1999 (Pubitemid 29269115)
65. Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639-647 (2003 (Pubitemid 36278582)
66. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am. Soc. Hematol. Educ. Program 331-349 (2003
67. Qazilbash MH, Wieder E, Rios R et al. Vaccination with the PR-1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood 104, 259 (2004) (Abstract
68. Qazilbash MH, Wieder E, Thall PF et al. PR-1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response event-free survival. Blood 110, 577 (2007) (Abstract
69. Rezvani K. PR-1 vaccination in myeloid malignancies. Expert Rev. Vaccines 7(7), 867-875 (2008
70. de Klein A, van Kesel AG, Grosvels G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300, 765-767 (1982 (Pubitemid 13224358)
71. Shtivelman E, Lifshitz B, Gale RP, Canani E. Fused transcript of abl and bcr genes in chronic myelogenus leukemia. Nature 315, 550-554 (1985 (Pubitemid 15021190)
72. Bocchia M, Wentworth PA, Southwood S et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85(10), 2680-2684 (1995
73. Clark RE, Dodi IA, Hill SC et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the bcr-abl b3a2 fusion protein. Blood 98, 2887-2893 (2001
74. Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br. J. Haematol. 109, 616-621 (2000 (Pubitemid 30415190)
75. Pawelec G, Max H, Halder T et al. BCR/ ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88, 2118-2124 (1996 (Pubitemid 26307914)
76. Pinilla-Ibarz J, Cathcart K, Korontsvit T et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95, 1781-1787 (2000 (Pubitemid 30120843)
77. Cathcart K, Pinilla-Ibarz J, Korontsvit T et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103, 1037-1042 (2004 (Pubitemid 38129569)
78. Bocchia M, Defina M, Aprile L et al. Complete molecular response in CML after p210 Bcr-abl1-derived peptide vaccination. Nat. Rev. Clin. Oncol. 7, 600-603 (2010
79. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of Bcr-abl peptide immunisation in chronic myeloidleukaemia: results of the EPIC study. Leukemia 21, 2287-2295 (2007 (Pubitemid 350011701)
80. Maslak PG, Dao T, Gomez M et al. A pilot vaccination trial of synthetic analog peptides derived from the BCRABL breakpoints in CML patients with minimal disease. Leukemia 22, 1613-1616 (2008
81. Jain N, Reuben JM, Kantarjian H et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 trial. Cancer 115, 3924-3934 (2009
82. Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111, 236-242 (2007
83. Greiner J, Schmitt M, Li L et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108, 4109-4117 (2006). (Pubitemid 44913282)